Welcome to AiCuris: The Powerhouse for Anti-Infectives
| AiCuris (from 'Anti-infective Cures') is a pharmaceutical company focused exclusively on the discovery, research and development of novel antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases. | Founded in 2006 from Bayer's virology and bacteriology research divisions, AiCuris today has an innovative pipeline of novel anti-infectives and a team of internationally regarded scientists and drug developers. With its tight focus on specialist markets with high medical need, the company is perfectly positioned for growth and success. |
AiCuris-Team receives German Future Prize / AiCuris-Team mit dem Deutschen Zukunftspreis ausgezeichnet
AIC649 Present Clinical Data
|
|
| AiCuris to Present Clinical Data on AIC649 at EASL |
- Single intravenous dose phase 1 trial showed that AIC649 was safe and well tolerated in all dose groups
- The trial provided evidence that AIC649 stimulates the immune system of chronic hepatitis B patients
Cooperation with Cyclenium
 |
| AiCuris to cooperate with Cyclenium Pharma to Develop Novel Anti-Infectives |
AiCuris and Cyclenium announced today the signing of a collaboration agreement focused on finding new pharmaceutical compounds for the treatment and prevention of bacterial and viral diseases.
Job Opportunities
 |
| Join AiCuris and its quest for novel Anti-Infectives |
We offer an exciting and challenging working enviroment in an innovative company with a world-class R&D Portfolio.